Comparison of SEER Treatment Data With Medicare Claims

Noone, Anne Michelle; Lund, Jennifer L.; Mariotto, Angela B.; Cronin, Kathleen A.; McNeel, Timothy S.; Deapen, Dennis; Warren, Joan L.

doi:10.1097/mlr.0000000000000073

Cited by 405 publications

(351 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

337

Contrasting

Unclassified

Order By: Relevance

“…Moreover, consistent reporting by Medicare of whether a patient received chemotherapy varies according to the primary cancer site, with overall sensitivity ranges between 7.2% and 84.4%. 43 Additionally, only intravenous or intravenous-equivalent drugs are claimed in Medicare, which would bias the data toward specific drugs. It is therefore important for future studies to further investigate the role of this important treatment modality.…”

Section: Neurooncologymentioning

confidence: 99%

Primary intramedullary spinal cord lymphoma: a population-based study

Yang

Garzón-Muvdi

Braileanu

et al. 2016

NEUONC

View full text Add to dashboard Cite

Background. Primary intramedullary spinal cord lymphoma (PISCL) is a rare diagnosis with poorly understood disease progression. Clarification of the factors associated with survival in PISCL patients is warranted. Methods. We conducted a population-based cohort study utilizing prospectively collected data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with histological diagnosis of primary lymphoma in spinal cord (C72.0) from 1973 to 2012 in the SEER database were included. Multivariable survival analysis between patient, lesion characteristics, and PISCL-related death was performed to adjust for confounding factors. Results. We included 346 PISCL patients in our study. Average age was 56.5 ± 17.8 years, with 62.7% being male. Racial distribution of these patients was white (87.6%), black (8.0%), and other (4.3%). More than half (55.8%) of patients were married. The most prevalent histology of PISCL was diffuse B-cell (46.2%), and the majority (55.2%) were low stage (Ann Arbor stage I/II). Most patients (67.9%) received radiation therapy. Average survival interval of patients with PISCL-related death (n=135, 39.0%) was 27.8 months. General cumulative survival probability at 1 year, 2 years, and 5 years was 73.8%, 67.9%, and 63.1%, respectively. Multivariable accelerated failure time (AFT) regression showed follicular lymphoma (HR:0.25, P=.008) and more recent diagnosis (HR:0.96, P<.001) was positively associated with PISCL-related survival. Conversely, nonwhite race (HR:1.69, P=.046), older age (HR:1.02, P<.001), unmarried status (HR:2.14, P<.001), and higher stage (HR:1.54, P=.022) were negatively associated with survival. Conclusions. Age, race, marital status, tumor histology, tumor stage, and year of diagnosis were associated with survival of PISCL. While most PISCL-related deaths occur within a 1-year period, subsequent slow progression was observed after the first year of survival.

show abstract

Section: Neurooncologymentioning

confidence: 99%

Primary intramedullary spinal cord lymphoma: a population-based study

Yang

Garzón-Muvdi

Braileanu

et al. 2016

NEUONC

View full text Add to dashboard Cite

show abstract

“…17,18 The Medicare files used included the Patient Entitlement and Diagnosis Summary File, the Outpatient file (institutional Medicare Part B claims), the Medicare Provider Analysis and Review file (inpatient Medicare Part A claims), the National Claims History file (provider Medicare Part B claims), Durable Medical Equipment files, and Medicare Part D file (prescription drug coverage for beneficiaries who purchase the benefit; ;60% of the beneficiaries). 19 …”

Section: Data Sourcementioning

confidence: 99%

Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, it remains possible that information from those patients who had missing data could significantly alter results in either direction. Additionally, there have been reports that SEER underreports RT use, potentially missing approximately 20 % of patients treated with RT, which could further confound any analysis of the effect of RT [39,40]. This inherently limits the length of follow up in this cohort, which only reached a median of 4 years.…”

Section: Metro/non-metro Effectsmentioning

confidence: 84%

Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes

2016

View full text Add to dashboard Cite

Myxopapillary ependymoma (MPE) is an exceedingly rare tumor histology. While surgery is clearly the treatment of choice, controversy exists regarding the role of adjuvant radiotherapy (RT). Using the Surveillence, epidemiology, and end results (SEER) database, we aimed to determine the epidemiology, prognostic factors, and treatment-related outcomes for MPE. A total of 773 cases were found in the SEER database. The incidence in the American population was found to be 1.00 per million person-years. On multivariate analysis, receipt of surgery (HR = 0.14, CI = 0.06-0.35, p < 0.001), receipt of RT (HR = 4.06, CI = 1.87-8.81, p < 0.001), age less than 30 (HR = 0.24, CI = 0.08-0.72, p = 0.01), and Caucasian race (HR = 0.37, CI = 0.13-0.996, p = 0.049) were statistically significant prognostic factors. The mean tumor size among those receiving RT (4.6 cm) was significantly larger than among those not receiving RT (3.2 cm, p = 0.0002). Those who lived in metropolitan areas were more likely to receive RT than those who did not. Given multiple previous studies show that RT improves PFS and the discrepancy in tumor size, selection bias is likely a significant contributor to the apparent negative impact of RT on OS. Regardless, surgery remains the most crucial aspect in the care of patients with MPE.

show abstract

Comparison of SEER Treatment Data With Medicare Claims

Abstract: Supplemental Digital Content is available in the text.

Cited by 405 publications

References 22 publications

Primary intramedullary spinal cord lymphoma: a population-based study

Primary intramedullary spinal cord lymphoma: a population-based study

Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma

Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes

Contact Info

Product

Resources

About